

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2018 WB

DESPATCHED ON 20TH MARCH 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A11; B56, B57; Cw1, Cw6; DR1, DR4; DQ5, DQ8

					Summary of Results												
					PBL				T-Cells				B-Cells				
					9	9	8	9	31	31	29	31	31	31	29	30	
					0	0	8	1	0	0	2	1	1	0	29	2	
					9	9	0	8	31	31	27	30	30	31	0	28	
					0	0	1	0	0	0	2	0	2	0	2	4	
					0.0%	0.0%	100.0%	11.1%	0.0%	0.0%	6.9%	3.2%	3.2%	0.0%	100.0%	6.7%	
					100.0%	100.0%	0.0%	88.9%	100.0%	100.0%	93.1%	96.8%	96.8%	100.0%	0.0%	93.3%	
Consensus					Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
HLA Antibody Specificity (Defined By CDC)					B8 DR3	B14+	DR1	A3	B8 DR3	B14+	DR1	A3	B8 DR3	B14+	DR1	A3	
					Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment		Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES		Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	Poor cell viability
11	YES	YES	YES		Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
12	YES	YES	YES		Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
20	YES	YES	YES		Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
23		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
24		YES	YES						Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	T-cells with DTT could not be reported as an invalid result was obtained due to poor viability of cells.
25		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
28		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
34		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
38	YES	YES	YES		Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
39		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
41		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
42	YES		YES		Negative	Negative	Positive	Negative					Negative	Negative	Positive	Negative	
45		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
51		YES	YES		Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
54		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
58		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
101		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
114		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
116		YES	YES						Negative	Negative	Positive	Positive	NT	NT	NT	NT	Low B-cell viability
117	YES				Negative	Negative	Positive	Positive									
136		YES							Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Low B-cell viability
145		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	
149	YES				Negative	Negative	Positive	Negative									
162		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
181		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
186		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
204		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
206		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
223		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
227		YES	YES						Negative	Negative	NT	Negative	Negative	Negative	Positive	Negative	Technical failure
268		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
284		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
311		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
315		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2018 WB

DESPATCHED ON 20TH MARCH 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0		0	0	0		0	0		0	70%	70%	70%	
11			2									95%	95%	60%	
12			20%									90%	90%	90%	
20	1	1	2	1					1	1	4	1	90%		80%
23					1	1	1	1	1	1	8	1		90%	90%
24					10%	10%	70%	10%	30%	30%	100%	60%		90%	90%
25					1	1	1	1	1	1	8	1		99%	99%
28					1	1	2	1	1	1	8	1		99%	95%
34					1	1	1	1	1	1	8	4		90%	90%
38	1	1	6	1	1	1	1	1	1	1	8	1	95%	100%	90%
39														98%	98%
41					5	5	5	5	10	10	80	10		95%	95%
42	<10%	<10%	20-40%	<10%					<10%	<10%	>80%	<10%	95%		90%
45					1	1	1	1	1	1	8	1		95%	85%
51	0	0	02-Apr	0	0	0	00-Jan	0	1	0	6	0	90%	90%	90%
54					5%	5%	5%	5%	5%	5%	100%	20%		95%	80%
58					5	5	5	5	10	10	100	10		95%	90%
101					1	1	1	1	1	1	8	1			
114					1	1	1	1	1	1	8	1			
116					1	1	1-2	1-2	0	0	0	0		90%	55%
117	1	1	8	6									85%		
136					1	1	1	1	1	1	6	1		98%	98%
145														100%	80%
149			06-Aug										88%		
162					1	1	1	1	1	1	8	1		100%	100%
181					1	1	1	1	1	1	8	1		100%	100%
186					0	0	0	0	0	0	8	0		99%	99%
204					2	2	4	2	1	2	8	1		90%	80%
206					0	0	0	0	0	0	8	0		90%	100%
223					1	1	2	1						95%	45%
227											6			98%	98%
268					1	1	1	1	1	1	6	1		80%	90%
284					1	1	1	1	1	1	8	1		99%	95%
311											8			80%	80%
315					1	1	1	1	1	1	6	1		80%	80%

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2018

DESPATCHED ON 20TH MARCH 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A11; B56, B57; Cw1, Cw6; DR1, DR4; DQ5, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	8	8	7	8	27	27	25	27	29	29	28	29				
Positive	0	0	6	0	0	0	1	0	1	0	28	0				
Negative	8	8	1	8	27	27	24	27	28	29	0	29				
NT	0	0	1	0	1	1	3	1	1	1	2	1				
% Positive	0.0%	0.0%	85.7%	0.0%	0.0%	0.0%	4.0%	0.0%	3.4%	0.0%	100.0%	0.0%				
% Negative	100.0%	100.0%	14.3%	100.0%	100.0%	100.0%	96.0%	100.0%	96.6%	100.0%	0.0%	100.0%				
Consensus	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative				
HLA Antibody Specificity (Defined By CDC)	B8 DR3	B14+	DR1	A3	B8 DR3	B14+	DR1	A3	B8 DR3	B14+	DR1	A3				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	Negative
11	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
15		YES	YES											Positive	Negative	Negative
20	YES		YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
24		YES	YES					NT	NT	NT	NT	Negative	Negative	Positive	Negative	Negative
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
38	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
39		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
41		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
42	YES		YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
51		YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Negative
54		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
58		YES	YES					Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
116		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	NT
149	YES			Negative	Negative	Positive	Negative									
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
227		YES	YES					Negative	Negative	NT	Negative	Negative	Negative	Positive	Negative	Negative
268		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
284		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2018

DESPATCHED ON 20TH MARCH 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	0		0	0	0		0	0	0	0		70%	70%	70%
11			2								8		95%	95%	60%
12											100%		90%	90%	90%
15					0	0	0	0	0	0	0	0		99%	99%
20	1	1	2	1					1	1	3	1	90%		80%
24					NT	NT	NT	NT	40%	30%	100%	30%		90%	90%
25					1	1	1	1	1	1	8	1		99%	99%
28					1	1	1	1	1	1	8	1		99%	95%
34					1	1	1	1	1	1	8	1		90%	90%
38	1	1	4	1	1	1	1	1	1	1	8	1	95%	100%	90%
39											8			98%	98%
41					5	10	10	10	10	10	80	15		95%	95%
42	<10%	<10%	20-40%	<10%					<10%	<10%	>80%	<10%	95%		90%
45					1	1	1	1	1	1	8	1		95%	85%
51	0	0	2-4	0	0	0	0	0	1	0	6	0	90%	90%	90%
54					5%	5%	5%	5%	10%	20%	100%	20%		95%	80%
58					5	5	30	5	10	10	100	10		95%	90%
101					1	1	1	1	1	1	8	1			
114					1	1	1	1	1	1	8	1			
116					1	1	01-Jan	1	0	0	0	0		90%	55%
149			6-8										88%		
162					1	1	1	1	1	1	8	1		100%	100%
181					1	1	1	1	1	1	8	1		100%	100%
186					0	0	0	0	0	0	8	0		99%	99%
204					2	4	4	2	1	1	8	1		90%	80%
206					0	0	0	0	0	0	8	0		90%	100%
227											6			98%	98%
268					1	1	1	1	1	1	8	1		80%	90%
284					1	1	1	1	1	1	8	1		99%	95%
311											8			80%	80%
315					1	1	1	1	1	1	6	1		80%	80%